Eduardo E Morales

US Patent:

20220186316, Jun 16, 2022

Filed:

Feb 20, 2020

Appl. No.:

17/432183

Inventors:

- Rockville MD, US
Jessica Richman - San Francisco CA, US
Daniel Almonacid - San Francisco CA, US
Rodrigo Ortiz - San Francisco CA, US
Eduardo Morales - San Francisco CA, US

Assignee:

PSOMAGEN INC. - Rockville MD

International Classification:

C12Q 1/6886
C12Q 1/689
G16B 20/20
G16B 30/00
G16B 5/00
G16B 50/00

Abstract:

A method for characterizing compatibility of a drug for a user includes collecting a set of samples from a set of individuals comprising a set of first individuals who respond to a therapy for a microbiome-related condition and a set of second individuals who do not respond to the therapy for the microbiome-related condition and determining one or more datasets based on the set of samples. A set of microbiome features is extracted from the one or more microbiome datasets, the microbiome features facilitating differentiation between individuals who respond and individuals who do not respond to the therapy. A companion diagnostics model is determined based on the set of microbiome features. The compatibility of the drug for the user is then determined using the companion diagnostics model.

US Patent:

20210128498, May 6, 2021

Filed:

Aug 14, 2018

Appl. No.:

16/638779

Inventors:

- Rockville MD, US
Jessica RICHMAN - San Francisco CA, US
Daniel ALMONACID - San Francisco CA, US
Valeria MARQUEZ - San Francisco CA, US
Ingrid ARAYA - San Francisco CA, US
Melissa ALEGRIA - San Francisco CA, US
Mario SAAVEDRA - San Francisco CA, US
Luis GOMEZ - San Francisco CA, US
Janyra ESPINOZA - San Francisco CA, US
Javier GIMPEL - San Franscisco CA, US
Eduardo MORALES - San Francisco CA, US
Rodrigo ORTIZ - San Francisco CA, US

International Classification:

A61K 31/165
A61K 31/045
A61K 31/047
A61K 31/085
A61K 31/05
A61K 31/4406
A61K 31/192
A61K 31/235
A61K 31/198
A61K 31/40
A61K 31/42
A61K 31/136
A61K 31/277
A61K 31/166
A61K 31/015
A61K 31/4196
A61K 31/415
A61K 31/14
A61K 31/4402
A61K 31/44
A61K 31/15
A61K 31/439
A61K 31/12
A61K 31/404
A61K 31/26
A61K 31/122
A61K 31/4035
A61K 31/133
A61K 31/16
A61K 31/4465
A61K 31/50
A61K 31/164
A61K 31/185
A61K 31/4015
A61K 31/4425
A61K 31/336
A61K 31/41
A61K 31/121
A61K 31/22
A61K 31/343
A61K 31/4192
A61K 31/517
A61K 31/428
A61K 31/502
A61K 31/36
A61K 31/365
A61K 31/4245
A61K 31/437
A61K 31/341
A61K 31/381
A61K 31/11
A61K 31/37
A61K 31/4418
A61K 31/4355
A61K 31/357
A61K 31/222
A61K 31/167
A61K 31/075
A61P 31/04
G16B 15/30

Abstract:

Embodiments of a method and/or system can include administering, to a patient with one or more conditions associated with at least one of TMA, TMAO, and/or derivatives thereof, a therapeutically effective amount of a compound for affecting inhibiting one or more CutC enzymes and/or CntA enzymes associated with microorganisms from at least one taxon from a set of microorganism taxa.

US Patent:

20200392481, Dec 17, 2020

Filed:

Mar 4, 2019

Appl. No.:

16/760939

Inventors:

- Rockville MD, US
Jessica Richman - San Francisco CA, US
Daniel Almonacid - San Francisco CA, US
Eduardo Morales - San Francisco CA, US
Constance Norris - San Francisco CA, US
Nicolas Ordenes - San Francisco CA, US
Pamela Nieto - San Francisco CA, US

International Classification:

C12N 15/10
B03C 1/28
B03C 1/01

Abstract:

Embodiments of the system and/or method can include and/or apply a magnetic device for facilitating a magnetic field for isolating the nucleic acid material from a sample, the magnetic device including a support component; and a set of magnetic pins attached to the support component and movable with at least three degrees of freedom when attached to the support component, where the set of magnetic pins provide adaptability to shapes of sample compartments of a sample container.

US Patent:

20200299763, Sep 24, 2020

Filed:

Oct 9, 2018

Appl. No.:

16/649234

Inventors:

- Rockville MD, US
Jessica Richman - San Francisco CA, US
Daniel Almonacid - San Francisco CA, US
Eduardo Morales - San Francisco CA, US
Luis Leon - San Francisco CA, US
Sara W. Bird - San Francisco CA, US
Juan Ugalde - San Francisco CA, US

International Classification:

C12Q 1/6869
C12Q 1/6806

Abstract:

Embodiments of a method and/or system (e.g., for improved single molecule sequencing, etc.) can include preparing a set of unique molecular identifier (UMI)-based molecules associated with a set of target nucleic acid sequences; facilitating generation of (e.g., generating, etc.) a set of tagged nucleic acid molecules based on the set of UMI-based molecules and a set of nucleic acid molecules corresponding to (e.g., including, etc.) the set of target nucleic acid sequences; and/or facilitating (e.g., performing, etc.) single molecule sequencing with the set of tagged nucleic acid molecules.

US Patent:

20200263171, Aug 20, 2020

Filed:

Sep 7, 2018

Appl. No.:

16/644559

Inventors:

- Rockville MD, US
Jessica Richman - San Francisco CA, US
Daniel Almonacid - San Francisco CA, US
Eduardo Morales - San Francisco CA, US
Rodrigo Ortiz - San Francisco CA, US
Nicolas Ordenes - San Francisco CA, US
Juan Jimenez - San Francisco CA, US
Cristian Bravo - San Francisco CA, US
Natalia Scioscia - San Francisco CA, US
Eduardo Olivares - San Francisco CA, US
Luis Leon - San Francisco CA, US
Paulo Covarrubias - San Francisco CA, US
Felipe Sepulveda - San Francisco CA, US
Felipe Melis - San Francisco CA, US

International Classification:

C12N 15/10
C12Q 1/6874

Abstract:

Embodiments of a method and/or system, such as for preparation of a normalized library for sequencing such as next-generation sequencing, can include one or more of: generating one or more normalized amplicon libraries; generating one or more normalized microbial community-associated libraries; and/or generating one or more normalized combined sequence libraries associated with amplicon-associated sequencing and microbial community-associated sequencing.

US Patent:

20200123539, Apr 23, 2020

Filed:

Jun 20, 2018

Appl. No.:

16/624816

Inventors:

- San Francisco CA, US
Jessica RICHMAN - San Francisco CA, US
Juan JIMINEZ - San Francisco CA, US
Rodrigo ORTIZ - San Francisco CA, US
Eduardo MORALES - San Francisco CA, US
Paulo COVARRUBIAS - San Francisco CA, US
Eduardo OLIVARES - San Francisco CA, US
Nicolas ORDENES - San Francisco CA, US
Luis LEON - San Franscisco CA, US

International Classification:

C12N 15/10

Abstract:

Embodiments of a method and/or system or library preparation for sequencing associated with microorganisms can include: preparing a set of unique molecular identifier (UMI)-based molecules associated with one or more targets; preparing a set of sequencing-based primers; generating a set of tagged target molecules based on the set of UMI-based molecules and one or more samples associated with the one or more targets; and/or generating a set of sequencing-ready tagged target molecules based on the tagged target molecules and the set of sequencing-based primers.

US Patent:

20180311310, Nov 1, 2018

Filed:

Mar 7, 2018

Appl. No.:

15/914925

Inventors:

- San Francisco CA, US
Jessica Richman - San Francisco CA, US
Daniel Almonacid - San Francisco CA, US
Melissa Alegria - San Francisco CA, US
Valeria Marquez - San Francisco CA, US
Eduardo Morales - San Francisco CA, US
Rodrigo Ortiz - San Francisco CA, US
Janet Torres - San Francisco CA, US
Paulo Covarrubias - San Francisco CA, US
Javier Gimpel - San Francisco CA, US
Ingrid Araya - San Francisco CA, US

International Classification:

A61K 38/16

Abstract:

Therapeutic compositions and an associated method for improving a Toll-like receptor (TLR)-related condition, including determining a set of peptide sequences associated with a microorganism-related modulator of a TLR, determining a first set of binding parameters for the set of peptide sequences in relation to the TLR, selecting a target subset of peptide sequences from the set of peptide sequences based on the first set of binding parameters, reengineering the target subset of peptide sequences based on mutating amino acid residues of the target subset of peptide sequences, determining a second set of binding parameters for the reengineered target subset of peptide sequences in relation to the TLR, and identifying a first peptide for use in a therapeutic composition for improving the TLR-related condition, based on the second set of binding parameters for the reengineered target subset of peptide sequences.

US Patent:

20180122510, May 3, 2018

Filed:

Dec 15, 2017

Appl. No.:

15/844139

Inventors:

- San Francisco CA, US
Jessica Richman - San Francisco CA, US
Daniel Almonacid - San Francisco CA, US
Catalina Valdivia - San Francisco CA, US
Rodrigo Ortiz - San Francisco CA, US
Inti Pedroso - San Francisco CA, US
Victoria Dumas - San Francisco CA, US
Paz Tapia - San Francisco CA, US
Eduardo Morales - San Francisco CA, US

International Classification:

G06F 19/28

Abstract:

Embodiments of a method and/or system for characterizing a diet-related condition for a user can include one or more of: generating a microbiome dataset for each of an aggregate set of biological samples associated with a population of subjects, based on sample processing of the biological samples; processing a supplementary dataset associated with one or more diet-related conditions for the set of users; and performing a diet-related characterization process for the one or more diet-related conditions, based on the supplementary dataset and/or microbiome features extracted from the microbiome dataset.